Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Hirogen
|
| gptkbp:approves |
gptkb:1985
|
| gptkbp:atccode |
L02 AE01
|
| gptkbp:available_on |
injectable solution
implant |
| gptkbp:brand |
gptkb:Lupron
gptkb:Eligard Viadur |
| gptkbp:casnumber |
74381-53-6
|
| gptkbp:chemical_formula |
C59 H84 N16 O13 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to leuprolide |
| gptkbp:discovered_by |
gptkb:Dr._Richard_J._Ablin
|
| gptkbp:dosage_form |
11.25 mg every 3 months
22.5 mg every 6 months 3.75 mg monthly 45 mg every 12 months |
| gptkbp:excretion |
urine
|
| gptkbp:financial_support |
avoid alcohol
report any unusual bleeding monitor for signs of adrenal insufficiency discuss fertility preservation options maintain regular follow-up appointments |
| https://www.w3.org/2000/01/rdf-schema#label |
leuprolide acetate
|
| gptkbp:interacts_with |
anticoagulants
hormonal therapies antidiabetic medications |
| gptkbp:lifespan |
3 hours
|
| gptkbp:mechanism_of_action |
Gn RH receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
long-acting
|
| gptkbp:route_of_administration |
intramuscular injection
subcutaneous injection |
| gptkbp:side_effect |
fatigue
weight gain mood changes hot flashes decreased libido |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:used_for |
gptkb:Oncology
gptkb:endometriosis precocious puberty uterine fibroids |
| gptkbp:bfsParent |
gptkb:Eligard
|
| gptkbp:bfsLayer |
6
|